Conatus Pharmaceuticals Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (24)

Latest Posts

About This Stock More About This Stock
E Conatus Pharmaceuticals Announces Two Poster Presentations At EASL Conference
Article By: Terry Chrisomalis
Saturday, April 22, 2017 4:34 PM EDT
Conatus Pharmaceuticals shows two posters at EASL conference that show a decrease in MELD might correlate with longer-term survival in transplant patients.
In this article: CNAT Also: NVS
Read
Conatus Pharmaceuticals Up On Novartis Partnership But Run Might Be Just Beginning
Article By: Terry Chrisomalis
Tuesday, January 24, 2017 8:37 AM EDT
Conatus has one major milestone in place for 2017 that could bring a substantial gain. This milestone is Novartis taking the option to license Emricasan.
In this article: CNAT Also: NVS, GALT, ICPT, GNFTF
Read
Conatus Soars On Novartis Deal, Early FDA Nod For Clovis Drug
Article By: Arpita Dutt
Wednesday, December 21, 2016 10:55 AM EDT
Conatus is ending the year on a high note with the company signing a lucrative deal with Swiss pharma giant, Novartis. Investors applauded the deal sending the company’s shares soaring 141.3%.
In this article: ALIOF, ALXN, BIIB, CLVS, GILD, CNAT, TSRO
Read
5 Biotech Stocks To Watch As Interest In NASH Increases
Article By: Arpita Dutt
Thursday, September 22, 2016 1:45 PM EDT
The market is suddenly abuzz about nonalcoholic steatohepatitis or NASH, a common but often “silent” liver disease. Several companies are working on developing treatments for NASH – the market could be worth billions of dollars.
In this article: ICPT, CNAT, GALT, ENTA, GLMD Also: AGN
Read
E Shares Of Conatus Up 22% On FDA Fast Track Designation For NASH Cirrhosis
Article By: Terry Chrisomalis
Thursday, February 4, 2016 2:38 AM EDT
Yesterday, shares of Conatus Pharmaceuticals closed the day up 22% after the company announced that the FDA had granted the company's drug, Emricasan, FDA fast track status for NASH Cirrhosis.
In this article: CNAT
Read

PARTNER HEADLINES

Latest Tweets for $CNAT

No tweets yet!